期刊文献+

免疫检查点抑制剂致皮肤不良反应及其管理的研究进展 被引量:2

Research progress and management strategies about skin adverse reactions of immune checkpoin inhibitors
下载PDF
导出
摘要 以免疫检查点抑制剂(ICIs)为代表的肿瘤免疫治疗改变了肿瘤治疗的格局,同时也产生了一个新的问题,即免疫治疗相关不良反应(irAEs)。其中,皮肤不良反应是ICIs所致的最常见的不良事件,主要包括斑丘疹、瘙痒和白癜风等。该文对癌症患者应用ICIs致皮肤不良反应的研究进展进行综述,旨在为ICIs的临床应用提供参考。
作者 李厚荣 邹振亚 LI Hourong;ZOU Zhenya
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2023年第3期187-189,共3页 Journal of Clinical Dermatology
  • 相关文献

参考文献17

二级参考文献44

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61 (2): 69-90.
  • 2Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist, 2008,13(Suppl 1): 5-13.
  • 3Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N EnglJ Med, 2008, 358(25): 2698-2703.
  • 4Tomasini P, Khobta N, Greillier L, et al. Ipilimumab: its potential in non- small cel/lung cancer. Ther Adv Med Oncol, 2012, 4(2): 43-50.
  • 5Dinglu L'ng adenocarcinoma. Nature, 2008, 455(7216) : 1069-107Getz 5.G' Wheeler DA, et aL Somatic mutations affect key pathways in.
  • 6Holt GE, Podack ER, Raez LE. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy, 2011, 8(1): 43-54.
  • 7Wang J, Zou ZH, Xia HL, et al. Strengths and weaknesses ofimmunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PLoS One, 2012, 7 (3): e32695.
  • 8Lynch TJ, Bondarenko IN, Luft A, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol, 2010, 28(15s): abstr7531, http:// www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail view &conflD=74&abstractID=53764.
  • 9Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination wit paclitaxel and carboplatin as first-line treatment in stage IIIb/W non-small1 cell lung cancer: results from a randomized, double-blind, multicenter phas1 II study. J Clin Oncol, 2012, 30(17): 2046-2054.
  • 10Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012, 366(26): 2443-2454.

共引文献148

同被引文献23

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部